Profile data is unavailable for this security.
About the company
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
- Revenue in USD (TTM)37.32m
- Net income in USD-5.99m
- Incorporated2006
- Employees52.00
- LocationSunshine Biopharma Inc333 Las Olas Way, Cu4 Suite 433FORT LAUDERDALE 33301United StatesUSA
- Phone+1 (954) 330-0684
- Fax+1 (514) 426-6101
- Websitehttps://www.sunshinebiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jaguar Health Inc | 11.79m | -40.29m | 3.04m | 49.00 | -- | 0.7861 | -- | 0.2579 | -54.06 | -54.06 | 12.98 | 1.53 | 0.2184 | 0.2099 | 8.78 | 240,510.20 | -76.04 | -90.27 | -152.77 | -144.36 | 81.92 | 75.33 | -348.22 | -458.25 | 0.5197 | -4.62 | 0.8759 | -- | 19.75 | 15.14 | 6.80 | -- | -- | -- |
| Functional Brands Inc | 6.80m | -377.56k | 3.25m | 32.00 | -- | 2.33 | -- | 0.4774 | -0.0546 | -0.0546 | 0.9614 | 0.0854 | 0.8873 | 0.3527 | 37.24 | 212,408.80 | -4.93 | -- | -9.96 | -- | 91.06 | -- | -5.55 | -- | 0.4419 | -0.8723 | 0.6346 | -- | -3.72 | -- | 54.93 | -- | -- | -- |
| China Pharma Holdings Inc | 4.05m | -3.19m | 3.48m | 224.00 | -- | 0.4191 | -- | 0.86 | -1.10 | -1.10 | 1.28 | 1.66 | 0.2769 | 2.17 | 14.52 | 18,090.54 | -21.80 | -18.69 | -35.67 | -37.95 | -10.94 | -1.14 | -78.72 | -44.96 | 0.1026 | -30.50 | 0.2884 | -- | -35.41 | -16.15 | -53.84 | -- | 16.49 | -- |
| Sonoma Pharmaceuticals Inc | 16.94m | -3.48m | 5.15m | 168.00 | -- | 1.32 | -- | 0.3043 | -2.20 | -2.20 | 10.65 | 2.30 | 1.23 | 3.26 | 5.78 | 100,815.50 | -25.26 | -29.32 | -34.95 | -40.47 | 37.68 | 36.22 | -20.54 | -32.35 | 2.05 | -- | 0.0146 | -- | 12.19 | -4.44 | 28.50 | -- | -17.24 | -- |
| 60 Degrees Pharmaceuticals Inc | 1.35m | -8.48m | 5.35m | 3.00 | -- | -- | -- | 3.95 | -23.04 | -23.04 | 2.93 | 4.32 | 0.1919 | 1.59 | 2.71 | 451,383.30 | -113.08 | -- | -148.26 | -- | 42.47 | -- | -589.17 | -- | 2.63 | -44.07 | 0.0342 | -- | 168.70 | -- | -111.48 | -- | -- | -- |
| Sunshine Biopharma Inc | 37.32m | -5.99m | 5.89m | 52.00 | -- | 0.226 | -- | 0.1577 | -2.03 | -2.03 | 10.74 | 5.31 | 1.21 | 2.09 | 10.12 | 717,764.30 | -19.47 | -68.65 | -23.80 | -89.02 | 33.01 | 32.79 | -16.06 | -81.12 | 2.09 | -209.95 | 0.00 | -- | 44.75 | 340.11 | -13.94 | -- | 370.33 | -- |
| CV Sciences Inc | 14.37m | -1.48m | 7.72m | 47.00 | -- | 5.02 | -- | 0.5374 | -0.008 | -0.008 | 0.078 | 0.0084 | 1.87 | 1.67 | 34.74 | 305,659.60 | -19.21 | -44.92 | -66.32 | -105.32 | 47.04 | 42.89 | -10.29 | -49.08 | 0.2125 | -2.02 | 0.3829 | -- | -1.87 | -21.80 | -177.18 | -- | -56.43 | -- |
| Tian'an Pharmaceutical Co Ltd | 10.65m | 3.14m | 8.00m | -- | 0.0445 | 0.0097 | 2.20 | 0.7511 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| Gelteq Ltd | 116.20k | -4.66m | 8.63m | 7.00 | -- | 0.7788 | -- | 74.30 | -0.4939 | -0.4939 | 0.0123 | 1.04 | 0.0078 | -- | 0.5155 | 16,600.46 | -31.47 | -17.38 | -40.60 | -19.16 | -- | -- | -4,011.74 | -4,507.46 | -- | -3.52 | 0.2106 | -- | -- | -- | -87.40 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| L1 Capital Global, Inc.as of 31 Dec 2024 | 142.24k | 2.90% |
| Citadel Securities LLCas of 30 Sep 2025 | 78.09k | 1.59% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 55.70k | 1.14% |
| DRW Securities LLCas of 30 Sep 2025 | 44.98k | 0.92% |
| Two Sigma Investments LPas of 30 Sep 2025 | 21.40k | 0.44% |
| Two Sigma Securities LLCas of 30 Sep 2025 | 17.18k | 0.35% |
| SBI Securities Co., Ltd.as of 30 Sep 2025 | 4.85k | 0.10% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2025 | 3.83k | 0.08% |
| UBS Securities LLCas of 31 Dec 2025 | 1.87k | 0.04% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2025 | 152.00 | 0.00% |
